Literature DB >> 766800

Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.

R D Rubens, R K Knight, J L Hayward.   

Abstract

Ninety-nine patients with advanced breast cancer were randomized to receive either cyclophosphamide continuously or a combination of cyclophosphamide, methotrexate, 5-fluorouracil and vinblastine given intermittently. The number and duration of objective responses were greater in patients receiving the combination but the differences between the two treatments did not achieve formal significance. The combination was logistically easier to manage and produced less toxicity.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 766800      PMCID： PMC2025018          DOI： 10.1038/bjc.1975.284

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

Review 1.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

2.  Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma.

Authors:  C Brambilla; M De Lena; G Bonadonna
Journal:  Cancer Chemother Rep       Date:  1974 Mar-Apr

Review 3.  Single and combination nonhormonal chemotherapy in breast cancer.

Authors:  S K Carter
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

Review 4.  Combination cancer therapy: Presidential address.

Authors:  E Frei
Journal:  Cancer Res       Date:  1972-12       Impact factor: 12.701

5.  Ten years' experience of sterioid assays in the management of breast cancer. A review.

Authors:  H Atkins; R D Bulbrook; M A Falconer; J L Hayward; K S MacLean; P H Schurr
Journal:  Lancet       Date:  1968-12-14       Impact factor: 79.321

6.  Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.

Authors:  L H Baker; C B Vaughn; M al-Sarraf; M L Reed; V K Vaitkevicius
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

7.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

8.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors:  B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

9.  Cyclical combination chemotherapy for advanced breast carcinoma.

Authors:  G P Canellos; V T Devita; G L Gold; B A Chabner; P S Schein; R C Young
Journal:  Br Med J       Date:  1974-02-09
  9 in total
  7 in total

Review 1.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three?

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer.

Authors:  R D Rubens; R J King; S Sexton; M J Minton; J L Hayward
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 4.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group.

Authors:  R T Chlebowski; R V Smalley; J M Weiner; L E Irwin; A A Bartolucci; J R Bateman
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

6.  Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

Authors:  P A Vasey; H Roché; D Bisset; C Terret; L Vernillet; A Riva; C Ramazeilles; N Azli; S B Kaye; C J Twelves
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

Review 7.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.